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Abstract
Background: Kawasaki Disease (KD) can cause potentially life-threatening coronary arteritis in young children, and
has a likely infectious etiology. Transcriptome profiling is a powerful approach to investigate gene expression in
diseased tissues. RNA sequencing of KD coronary arteries could elucidate the etiology and the host response, with
the potential to improve KD diagnosis and/or treatment.
Methods: Deep RNA sequencing was performed on KD (n = 8) and childhood control (n = 7) coronary artery tissues,
revealing 1074 differentially expressed mRNAs. Non-human RNA sequences were subjected to a microbial discovery
bioinformatics platform, and microbial sequences were analyzed by Metastats for association with KD.
Results: T lymphocyte activation, antigen presentation, immunoglobulin production, and type I interferon response
were significantly upregulated in KD arteritis, while the tumor necrosis factor α pathway was not differentially
expressed. Transcripts from known infectious agents were not specifically associated with KD coronary arteritis.
Conclusions: The immune transcriptional profile in KD coronary artery tissues has features of an antiviral immune
response such as activated cytotoxic T lymphocyte and type I interferon-induced gene upregulation. These results
provide new insights into the pathogenesis of KD arteritis that can guide selection of new immunomodulatory
therapies for high-risk KD patients, and provide direction for future etiologic studies.
Keywords: Kawasaki disease, Coronary artery aneurysm, Arteritis, Childhood, Innate immune response, Acquired
immune response
Background
Transcriptome profiling of infected tissues, or “dual RNA-
sequencing” allows for unbiased simultaneous gene ex-
pression evaluation of pathogen and host [1]. Kawasaki
Disease (KD) is an acute febrile illness of young childhood
that can cause medium-sized muscular arteritis, most crit-
ically affecting the coronary arteries, and a large body of
clinical, epidemiologic, and experimental evidence points
to an infectious cause [2, 3]. Severely affected infants and
young children develop coronary artery aneurysms and
are at risk for myocardial infarction and sudden death
[3]. It has been difficult to improve diagnosis and treat-
ment of KD because of a lack of understanding of the
etiology and pathogenesis. The purpose of this study
was to identify specific cellular pathways and infectious
agents in KD coronary arteritis by transcriptome profil-
ing, to elucidate the pathogenesis of the disease.
Methods
Patients and controls
The study was approved by the Institutional Review
Board of The Ann & Robert H. Lurie Children’s Hospital
of Chicago. The KD cases occurred widely throughout the
United States over the last three decades. Informed con-
sent was obtained at the primary institution in five cases;
in the remaining three KD cases and all the control cases,
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tissues were archival and de-identified. Six KD patients
were male and two were female. Five were Caucasian, one
Hispanic, one African-American, and one of unknown
ethnicity. The mean age of the KD patients was 15 months
with a median age of 7 months. Eight control cases were
male and 3 were female. The mean age of the control
patients was 15 months with a median age of 5 months.
Data deposited at Gene Expression Omnibus, National
Center for Biotechnology Information (GEO) cannot be
potentially used to re-identify individuals from the study.
Clinical information on the KD patients is given in Table 1.
All patients had coronary artery abnormalities and all were
fatal cases except for KD3, who underwent heart trans-
plant; the coronary artery light and electron microscopic
findings for KD patients 1–3 and 5–8 are described in our
pathologic study [4] (Tables 1 and 2). Additional informa-
tion for KD patient 4 is provided in Additional file 1: Sup-
plemental Methods. Childhood controls had normal
coronary artery histology; their diagnoses are given in
Table 2. Three of the KD patients did not receive any
therapy between fever onset and death/transplant and
one received only aspirin and dipyridamole (KD1-4,
“untreated” group). One patient received IGIV alone,
two received IGIV and corticosteroid, and one patient re-
ceived IGIV, corticosteroid, and infliximab (KD5-8,
“treated” group).
RNA isolation and quality control analyses
RNA was isolated from formalin-fixed, paraffin-embedded
KD and control tissue sections using the RNeasy kit de-
signed for these tissues (Qiagen, Valencia, CA). RNA sam-
ples meeting the quality standards described in Additional
file 1: Supplemental Methods were subjected to ribosomal
RNA subtraction using the Ribo-Zero human rRNA sub-
traction kit (Epicentre, Madison, WI) prior to sequencing.
High-throughput RNA sequencing
Preparation of cDNA libraries and Illumina HiSeq2000
RNA sequencing were performed at the University of
Utah Microarray Core Facility (Salt Lake City, UT).
Sequence alignment and normalization
For RNA sequencing analysis, TopHat (Bowtie version
2.1.0) [5] was used to align reads to the human refer-
ence GRCh37-lite (accession id: GCA_000001405.1),
and HTseq version 0.6.1 in “union” mode [6] was used
to determine read counts. DESeq was used for variance
stabilizing normalization and determination of differential
expression based on a model using the negative binomial
distribution [7]. Additional information on alignments can
be found in Additional file 1: Table S1.
Pathways analysis
The data were analyzed using iReport™ (Ingenuity Sys-
tems, Redwood City, CA, www.ingenuity.com), with fold
change of at least 1.5 and q-value of ≤ 0.05 as signifi-
cance criteria for differentially expressed genes between
KD patients and controls. The primary analysis was of
CA gene expression in 8 KD patients compared to 7
childhood controls. Subgroup analyses were also per-
formed for the CA transcriptome of 4 untreated KD pa-
tients compared to 7 controls, and 4 treated KD patients
compared to 7 controls.
Cluster and principal components analyses
Hierarchical cluster analysis with mean linkage function
(hclust function in base R) was used to cluster the
samples by expression profiles. Principal components
analysis was run to estimate the variances explained by
the first and second principal components (prcomp
function in base R).
Real-time PCR
Differential expression by real-time PCR were performed
on KD and control coronary artery formalin-fixed, paraffin-
embedded tissue RNAs using the comparative CT method
[8]. The differential expression was compared using vari-
ances estimated by empirical Bayes models. We controlled
for false discovery rate to account for multiple testing under
dependency using adjusted p-values [9].
Table 1 Clinical data on Kawasaki disease children whose coronary artery tissues were tested in this study
Case # Time since onset KD therapy Category Pathology study case # [4] RNA tested by
KD1 2.5 weeks None Untreated 4 HTS, PCR
KD2 4 weeks ASA, dipyridamole Untreated 16 HTS
KD3 5 months None Untreated 26 HTS, PCR
KD4 7 months None Untreated NA HTS, PCR
KD5 3.5 weeks IGIV, ASA, steroid Treated 11 HTS, PCR
KD6 4 weeks IGIV, ASA, steroid, infliximab Treated 13 HTS, PCR
KD7 3 weeks IGIV, ASA Treated 7 HTS, PCR
KD8 5 weeks IGIV, ASA, steroid Treated 18 HTS
HTS high-throughput RNA sequencing, PCR real-time reverse transcriptase PCR, ASA aspirin
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Microbial analyses
Viral sequences were identified based on nucleotide and
translated amino acid sequence alignments as described
[10]. Sequences from cellular microbes were identified
using Real Time Genomics Map and Species programs,
version 3.4.3 (Real Time Genomics, Hamilton, New
Zealand, http://realtimegenomics.com) to align sequences
against the Human Microbiome Project’s microbial refer-
ence genome database (http://hmpdacc.org/HMREFG/),
and by classifying sequences with MetaPhlAn [11]. Meta-
stats was used to test for sequences that were differentially
abundant in KD cases and controls [12].
Results
Deep RNA sequencing of KD and pediatric control
coronary arteries
To evaluate the transcriptome of KD arteritis, we com-
pared the RNA expression of KD coronary artery tissues
with those of non-inflamed coronary artery tissues from
pediatric patients with non-KD illnesses as controls. The
analysis pathway is shown in Fig. 1. The pathologic fea-
tures of the coronary arteries in the KD patients are
described in our prior study [4]; all showed subacute/
chronic arteritis and luminal myofibroblastic prolifera-
tion (Fig. 2a). All primary data can be accessed at NCBI
GEO GSE64486. Sequencing yielded a total of 40–120
million RNA sequencing reads/sample. About 50–90 %
of the reads for each tissue sample mapped to the hu-
man genome. DEseq analysis yielded 1074 genes that
were differentially expressed in 8 KD compared with 7
childhood control coronary arteries (Fig. 2b and c and
Additional file 1: Table S2). Strikingly, heat map analysis
of differentially expressed genes in KD and control cor-
onary artery tissues showed that gene expression in KD
patients did not cluster by age, time since onset of KD,
or treatment, supporting the analysis of the 8 KD tissue
samples together (Fig. 2b and c). The lack of clustering
by time since onset of KD is consistent with our pathologic
study demonstrating persistence of subacute arteritis for
months to years after the onset [4]. It is notable in Fig. 2b
and c that the gene expression profiles of the two patients
with the longest time interval since onset, KD3 and KD4,
fall directly in the center of the KD patient group. The lack
of clustering by treatment is likely explained by persistent
arteritis in the treated patients despite therapy. Principal
components analysis also demonstrated that gene expres-
sion profiles in treated and untreated KD patients were
not distinguishable (Additional file 1: Figure S1).
T lymphocyte activation and Type I interferon-induced
genes are upregulated in KD coronary arteries
Pathways associated with activated T lymphocyte func-
tion were significantly upregulated in KD coronary ar-
teries (Table 3, Additional file 1: Table S3). Activation
of cytotoxic T lymphocyte genes is consistent with our
prior report demonstrating CD8 protein expression in
KD coronary arteries [13] (Fig. 3a). Although molecular
pathways associated with natural killer cell signaling
were identified as upregulated in KD coronary arteries
(Table 3), there is marked overlap in gene expression by
natural killer cells and activated cytotoxic CD8 T lympho-
cytes [14], and the lack of an antibody that can reliably
distinguish these two cell types by immunohistochemistry
did not allow us to determine whether natural killer cells
were present in the coronary artery inflammatory infil-
trate. In addition, many immunoglobulin genes were up-
regulated, consistent with our prior immunohistochemical
studies showing immunoglobulin protein expression in
the inflammatory infiltrate [15].
Many type I interferon-stimulated genes [16–18] were
upregulated (Table 4, Fig. 3b). This contrasts with previ-
ously reported findings in the peripheral blood of acute
Table 2 Clinical data on control children whose coronary artery tissues were tested in this study
Control # Diagnosis RNA tested by
C1 Enterobacter sepsis, pulmonary hemorrhage, neurologic devastation from herpes simplex virus encephalitis HTS
C2 Pneumococcal meningitis, disseminated intravascular coagulation HTS, PCR
C3 Prematurity, neurologic devastation secondary to Serratia meningitis, chronic lung disease HTS
C4 Meconium aspiration, pulmonary hemorrhage HTS
C5 Developmental delay, seizures, fever HTS
C6 Prematurity, cerebral hemorrhage, bronchopulmonary dysplasia, and pneumonia HTS, PCR
C7 Cholestasis, renal tubular acidosis, agenesis corpus callosum, dehydration HTS
C8 Congenital diaphragmatic hernia, pulmonary hypoplasia PCR
C9 Hypotonia, subdural and liver hematomas PCR
C10 Congenital sacrococcygeal teratoma PCR
C11 Hypoplastic left heart, respiratory syncytial virus infection PCR
HTS high-throughput RNA sequencing, PCR real-time reverse transcriptase PCR
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KD patients, in which interferon-stimulated gene expres-
sion was reported to be strikingly absent [19]. This result
emphasizes the limitations of peripheral blood studies in
determining gene expression changes in diseased target
tissues.
Antigen presentation and dendritic cell pathways are
activated in KD arteritis
Pathways associated with dendritic cells and antigen pres-
entation were significantly upregulated (Table 3). The acti-
vating Fc receptor genes FCGR2A, FCGR2C, FCGR3A,
and FCGR3B, commonly expressed on dendritic cells,
were upregulated, while the inhibitory receptor FCGR2B
and the macrophage marker FCGR1 were not differen-
tially expressed.
Macrophage and neutrophil-specific gene expression are
not prominent
Genes commonly expressed by monocyte/macrophages
[20] were not differentially expressed, such as CD68,
FCGR1A, CSF1R, CD163, and CD14. This contrasts with
a view of KD arteritis as a primarily macrophage-mediated
process [21]. Neutrophil-associated genes were not signifi-
cantly altered. Eosinophils are a component of the unique
subacute/chronic arteritis infiltrate, and SIGLEC8, which
is selectively expressed by eosinophils and mast cells [22],
was upregulated.
Pattern recognition receptor genes are differentially
expressed in KD arteritis
Pattern recognition receptor genes and Toll-like receptor
signaling pathways were differentially expressed (Table 3).
Many C-type lectin and cytosolic pattern-recognition re-
ceptors were differentially expressed (Additional file 1:
Table S2). The most highly upregulated gene in the Toll-
like receptor family was TLR7, with TLR1, TLR6, TLR8,
TLR10, TLR5, and TLR2 also upregulated. TLR3, TLR4,
and TLR 9 were not differentially expressed. TLR7 is
thought to be exclusively expressed by plasmacytoid den-
dritic cells, which secrete type I interferons in response to
viral infection [23].
Genes involved in lipid and lipoprotein metabolism are
differentially expressed in KD arteritis
Many of the differentially expressed genes have functions
in both lipid metabolism and immune response. Genes
commonly associated with promotion of atherogenesis,
such as LDLR and PLA2G2A, were downregulated. A not-
able feature was the downregulation of surfactant associ-
ated genes SFTPA1, SFTPA2, SFTPB, SFTPC, SFTPD,
SFTA2, and SFTA3. It is possible that the marked down-
regulation in surfactant expression impairs the modula-
tion of inflammatory responses in coronary artery smooth
muscle cells in KD arteritis [24, 25].
Fig. 1 Workflow to determine differentially expressed molecular pathways in KD coronary arteries
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Fig. 2 a Left, coronary artery tissue section from KD patient 6, demonstrating subacute chronic (SA/C) inflammation and luminal myofibroblastic
proliferation (LMP) with resultant narrowing of the arterial lumen that is filled with blood. Right, coronary artery tissue section from control
patient 4, demonstrating normal histology without inflammation. Hematoxylin and eosin stains, M =media, A = adventitia; b Heatmap demonstrating
differential gene expression in KD and control coronary artery tissues, with low expression in blue and high expression in red; c KD coronary artery
gene expression does not cluster by treatment, patient age, or time since onset of KD. The lack of clustering of gene expression by treatment is likely
due to persistent arteritis in the treated patients despite therapy
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Cytokine and growth factor pathways that were not
differentially expressed
Tumor necrosis factor receptor 1 and 2 signaling pathways
were not differentially expressed (Fig. 3c). Transform-
ing growth factor β signaling was also not differentially
expressed. Interestingly, none of the following genes
were differentially expressed in this dataset: matrix me-
talloproteinases (with the exception of MMP27, which
just met significance criteria), vascular endothelial growth
factors-A, B, or C, platelet derived growth factors-A,B,C,
or D, vascular cell adhesion molecule 1, or fibroblast
growth factor 2. The interleukin-1 signaling pathway was
not differentially expressed. One IL-1 family member, IL-
18, was upregulated. However, regulatory IL-1 family
member IL1RN (IL1RA) was also upregulated, and IL1RL1
(IL33R, ST2) was markedly downregulated.
RNA sequencing results are validated by real-time reverse
transcriptase PCR assays
PCR assays confirmed significant upregulation of CD74,
CD69, IL18, HLA-F, NLRC5, and CD226, genes involved
in antigen presentation and dendritic cell function, in
KD CA tissues (Additional file 1: Table S4). Genes that
we previously identified as upregulated by real-time
PCR on KD and control CA, including CD84, PIM2,
POSTN, IL10RA, IL2RA, IQGAP2, and ITGA4 [26–28]
were also identified as significantly upregulated by this
transcriptome analysis, providing additional validation of
our results.
Differentially expressed genes encoding secreted proteins
are candidate biomarkers of KD subacute/chronic arteritis
Extracellular genes encoding secreted proteins accounted
for 155 of the differentially expressed genes (Additional
file 1: Table S5), 93 were upregulated, and 13 were im-
munoglobulin genes. The other 80 proteins are candidate
diagnostic/prognostic biomarkers of KD arteritis; such
biomarkers are urgently needed for diagnosis and moni-
toring of KD patients. We have previously reported one of
the upregulated proteins, periostin, as a potential diagnos-
tic biomarker of KD [28].
Table 3 Top 25 upregulated pathways in kawasaki disease coronary arteries
Upregulated pathways # of differentially expressed genes p-value
Primary immunodeficiency signaling 26 5.65E-21
Communication between innate and adaptive immune cells 30 1.08E-17
iCOS-iCOSL signaling in T helper cells 32 3.12E-17
Altered T cell and B cell signaling in rheumatoid arthritis 29 3.84E-17
B cell development 17 3.62E-14
CD28 signaling in T helper cells 28 1.35E-12
Role of NFAT in regulation of the immune response 33 6.43E-12
PKCθ signaling in T lymphocytes 27 8.5E-12
Autoimmune thyroid disease signaling 17 5.1E-11
Hematopoiesis from pluripotent stem cells 17 1.06E-10
T cell receptor signaling 23 1.38E-10
Antigen presentation pathway 14 6.89E-10
Calcium-induced T lymphocyte apoptosis 18 7.03E-10
Crosstalk between dendritic cells and natural killer cells 21 9.61E-10
Systemic lupus erythematosus signaling 34 1.8E-09
Allograft rejection signaling 20 3.16E-09
Graft-versus-host disease signaling 15 3.7E-09
T helper cell differentiation 18 4.41E-09
CTLA4 signaling in cytotoxic T lymphocytes 20 4.84E-09
Nur77 signaling in T lymphocytes 16 6.42E-09
Dendritic cell maturation 29 8.49E-09
Agranulocyte adhesion and diapedesis 29 2.97E-08
OX40 signaling pathway 19 3.48E-08
Natural killer cell signaling 21 5.32E-08
Hepatic fibrosis/Hepatic stellate cell activation 29 7.53E-08
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No known viral, bacterial, or fungal sequences were
associated with KD
Human and environmental viral sequences were identi-
fied in KD and control coronary artery samples, but
none were associated with KD samples (Fig. 4). We
identified the recently described parvovirus-circovirus
hybrid virus as a contaminant in both KD and control
datasets; this virus has previously been shown to con-
taminate certain nucleic acid isolation kits, and its ini-
tial report as a potential cause of human viral hepatitis
highlights the importance of caution in performing
pathogen discovery studies [29]. No specific bacterial
or fungal sequences were associated with KD samples
(data not shown).
Discussion
Identification of upregulated immune pathways in CA
target tissues significantly advances the understanding of
KD pathogenesis, and in particular enhances knowledge
of the molecular immunology of subacute/chronic cor-
onary arteritis. Therapy aimed at reducing CA inflam-
mation in KD patients has been largely empiric, because
of a lack of information regarding the immunopathogen-
esis of disease in the target CA tissues.
Previous transcriptome studies have been performed
only on peripheral blood of KD patients. Those studies
revealed neutrophil activation prior to treatment with
IGIV, consistent with elevated peripheral blood neutro-
phil counts during the acute febrile illness [19, 30], and
consistent with the neutrophilic necrotizing arteritis of
medium-sized muscular arteries such as the CA that oc-
curs in the first two weeks after fever onset [4]. Identifi-
cation of upregulated immune responses in the CA
target tissues of KD provides previously unavailable infor-
mation with potential therapeutic implications. A recent
rigorous study demonstrated that fold changes in induced
immune response proteins are particularly dominated by
mRNA level changes, whereas expression of cytoskeletal,
metabolic, ribosomal, and mitochondrial proteins are pri-
marily controlled by translation and degradation rates
[31], making it likely that the transcriptional upregulation
identified in this study is accompanied by translational
upregulation.
We found that T lymphocyte activation, antigen pres-
entation and dendritic cell function, immunoglobulin
production, and type I interferon response are the most
significantly upregulated molecular pathways and processes
in KD subacute/chronic arteritis. These are compatible
Fig. 3 Expression levels of gene families in KD compared with control coronary arteries. a Upregulation of activated cytotoxic CD8 T lymphocyte
genes in KD, b Upregulation of type I interferon-induced genes in KD, c Lack of differential expression of tumor necrosis factor α-induced genes
in KD. Blue indicates low expression and red high expression
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with the gene polymorphisms resulting in a decrease in
negative regulation of T lymphocyte responses that
have been associated with the development of KD and
CA abnormalities [32, 33]. It is also of interest that sev-
eral type I interferon-induced proteins such as CXCL9
and CXCL10 are potential biomarkers of KD [34, 35].
Our study did not identify differential expression of the
tumor necrosis factor α pathway, the transforming growth
factor β pathway, matrix metalloproteinases-2,-3, −9 and-
12, vascular endothelial growth factors, or platelet derived
growth factors, which have been postulated previously
as important players in the pathogenesis of KD arteritis
by us and others [36–39]. These findings do not ex-
clude a role for the previously proposed pathways and
molecules in KD vasculitis pathogenesis, in particular
because gene expression does not always correlate with
protein expression. However, changes in mRNA abun-
dance of immune response genes play the dominant
role in dynamic changes in protein levels, whereas the
proteome of proteins performing basic cellular func-
tions are predominately regulated at the level of protein
translation or degradation [31]. Therefore, the immune
response genes found to be upregulated in our study
may play the most prominent role in KD subacute/
chronic vasculitis.
IGIV non-responders are a high-risk group of pa-
tients who are often administered additional immuno-
modulatory therapies with the goal of improving CA
outcomes. However, identifying optimal therapies for
such patients has been difficult, because the activated
immune pathways in KD CA have been unknown. Be-
cause severe CA outcomes can occur even in IGIV-
treated patients, particularly young infants, initial studies
of combination primary therapies consisting of IGIV with
a second immunomodulatory agent have been performed.
A single dose of methylprednisolone with IGIV for pri-
mary therapy of KD did not improve outcomes [40],
while in the more recent RAISE study, IGIV with a 3–4
week course of prednisolone for primary therapy of
high-risk Japanese children did improve outcomes [41].
It seems plausible that a 2–4 week corticosteroid therapy
course would be more effective in modulating the promin-
ent T lymphocyte responses demonstrated in KD CA tis-
sues in our study than would a single large dose of
Table 4 Type I interferon-stimulated genes differentially expressed
in KD compared with childhood control coronary arteries
Gene Fold change q-value
ADAMDEC1 20.5 2.6e-18
AIM2 3.7 0.023
ANKRD22 10.2 1.9e-07
APOBEC3G 3.5 0.023
AQP9 4.9 1.7e-06
BTN3A3 3.5 0.020
C15orf48 4.0 0.0004
CCL5 6.5 1.1e-05
CD69 10.3 2.6e-09
CD74 7.7 3.5e-05
CLEC2B 3.0 0.006
CLEC4D 3.4 0.029
CLEC4E 3.9 0.011
CXCL9 48.0 1.2e-14
CXCR4 14.7 2.9e-12
EPSTI1 4.9 0.002
FAM46C 5.3 0.001
GBP2 4.3 0.0005
GBP5 14.7 8.8e-14
GK 2.6 0.0008
HLA-F 2.8 0.007
HSH2D 2.9 0.044
IFI30 4.6 0.0002
IFI44 3.3 0.022
IFI44L 4.2 4.6e-06
IFIT2 3.3 0.029
IL1RN 2.8 0.020
MSR1 5.8 0.002
MT1H 1.7 0.0009
MX1 4.2 0.0002
MX2 4.7 0.0005
NCF1 4.1 0.004
OAS1 4.3 0.008
OAS2 5.0 0.0005
OLR1 42.2 7.6e-19
RGS1 17.0 1.3e-10
RSAD2 4.1 0.002
STAP1 7.4 1.3e-07
TAGAP 6.2 0.0001
TFEC 7.4 0.0009
TNFSF13B 4.2 0.010
XAF1 3.3 0.005
ZBP1 5.6 0.002
Table 4 Type I interferon-stimulated genes differentially expressed
in KD compared with childhood control coronary arteries
(Continued)
AGPAT9 −2.4 0.0008
CES1 −4.1 4.0e-05
FNDC4 −2.0 0.006
MT1M −2.5 0.029
SAA1 −5.3 6.4e-14
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methylprednisolone. The use of a tumor necrosis factor-α
inhibitor (infliximab) in combination with IGIV for pri-
mary therapy did not result in significantly improved out-
comes [39]. The lack of differential expression of the
tumor necrosis α pathway in the present study suggests
that this cytokine may not be an optimal therapeutic tar-
get for subacute/chronic arteritis. Chronic type I inter-
feron responses can be involved in the pathogenesis of
persistent viral infections and autoimmune diseases
[42, 43], and therapies to ameliorate this response are
under study [44]. Because 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors appear to have modu-
latory effects on cytotoxic T lymphocyte responses,
therapeutic trials of these drugs in KD arteritis appear
warranted [45].
Bioinformatics analysis did not reveal any known
viral, bacterial, or fungal sequences associated with KD
coronary artery tissues. There are many potential expla-
nations for the lack of identification of a causative in-
fectious agent in these tissues. The agent could be in a
quantity too low to detect, or could have been eradi-
cated by the immune response earlier in the disease
course, with subacute/chronic arteritis the result of an
inability to resolve the initial inflammatory response.
Another possibility is a “new” agent not present in estab-
lished reference databases, making it difficult to identify.
Interestingly, our study revealed many upregulated type I
interferon-induced genes in KD CA, which supports our
prior hypothesis of a presently unidentified virus as the
causative agent based on ultrastructural, immunofluores-
cence, and RNA evidence [2]. We are presently analyzing
KD-associated sequences that remain unassigned in at-
tempts to identify a putative “new” virus, using novel
bioinformatics approaches, such as assembly without a
reference genome [46].
Our study has strengths and limitations. The number
of CA specimens available for study was limited by many
factors. These factors include the fact that CA tissues
are not available for research in the living patient,
reporting of KD deaths is not required, autopsy is some-
times not obtained in fatal cases or is delayed so that
RNA quality is inadequate for molecular studies, and
heart tissues following transplantation are often not op-
timally preserved for molecular studies. Additional dif-
ferentially expressed genes might have been identified if
more CA tissues were available for sequencing. Because
necrotizing arteritis is observed in the first 2 weeks after
fever onset, when fatalities or surgical interventions are
rare, our study would not reveal the transcriptome of
necrotizing arteritis [4]. However, subacute/chronic ar-
teritis begins in the first two weeks after fever onset and
can persist for months to years, leading to significant
CA damage [4]. Understanding its pathogenesis is par-
ticularly important for IGIV non-responders and for
children with persistent coronary artery abnormalities,
who may have chronic arteritis. KD patients in our study
died or underwent cardiac transplant at various intervals
since KD onset, at various ages, and had received a var-
iety of therapies. However, gene expression did not clus-
ter by these factors (Fig. 2b and c). Tissue samples were
from Caucasian, Hispanic, and Black children but not
Asian children, and from both genders, which could
have affected gene expression results. As sequencing
technology and bioinformatics methods improve, add-
itional studies on larger numbers of KD CA samples, es-
pecially from Japan, would be informative to confirm
Fig. 4 Heatmap showing viral sequences identified in KD and control coronary artery samples; none were KD-associated by Metastats analyses
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and extend the present findings. Over several decades,
we have developed what is likely the largest KD tissue
bank outside of Japan, enabling us to identify the tran-
scriptome of subacute/chronic KD arteritis in this study.
A complete understanding of KD pathogenesis will re-
quire integration of genomic, transcriptome, and prote-
ome studies, and identification of the etiologic agent(s).
Conclusions
In summary, the immune transcriptome of KD arteritis in
the patients studied here reveals a marked activation of
cytotoxic and helper T lymphocytes and dendritic cells,
with upregulation of type I interferon responses. These re-
sults support a putative viral etiology of KD, and provide
preliminary information on the immunopathogenesis of
KD coronary arteritis that can inform selection of new im-
munomodulatory therapies for clinical trials in high-risk
patients with this potentially fatal arteritis of childhood.
Supporting data can be accessed at NCBI GEO
GSE64486.
Additional file
Additional file 1: Supplemental Methods. Table S1. RNA sequencing
metrics. Table S2. All differentially expressed genes (8 KD cases vs 7
controls). Table S3. Dysregulated molecular pathways (8 KD cases vs 7
controls). Table S4. Differential expression of genes involved in antigen
presentation and dendritic cell function in KD compared to control
coronary arteries by real-time reverse transcriptase PCR assays. Table S5.
Extracellular genes dysregulated in 8 KD coronary arteries compared with 7
childhood control coronary arteries. Figure S1. Principal components analysis
of all genes in 8 KD (4 treated and 4 untreated) and 7 childhood control
coronary artery tissues demonstrates that gene expression of untreated (red
dots) and treated (black dots) KD patients are not distinguishable. (PDF 382
kb)
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